LIfT BioSciences announces breakthrough preclinical data demonstrating dual mode of action
LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid
LIfT BioSciences is developing a breakthrough allogeneic innate cell therapy platform that produces different types of Immunomodulatory Alpha Neutrophils (IMANs). LIfT's focus is on producing an exceptional type of anti-cancer alpha neutrophil with enhanced cytotoxic and immunomodulatory properties.
Our mission is to develop affordable curative therapies for solid tumours with high unmet medical need.